PTO/SB/08 (09-06)

Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO				Complete if Known			
	INFORMATIO	N DISCLO	SURE	Application Number	10/576,575	10/576,575	
	STATEMENT	BY APPLI	CANT	Filing Date April 20, 2006		006	
Date Submitted: October 1, 2007				First Named Inventor	Robyn Lyni	ne Ward	
				Art Unit	1634		
(use as many sheets as necessary)			cessary)	Examiner Name	-Unknown-	Amanda Shaw	
Sheet	1	of	2	Attorney Docket Number	037775-010	07	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant		
	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
	A5	US-2003/124600 A1	07-03-2003	Sidranksy			
	A6	US-6,235,474 B1	05-22-2001	Feinberg			
1							
	-						

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	To
	A7	WO 01/75175 A2	10-11-2001	University of Southern California		
	A8	WO 2005/001141 A3	01-06-2005	Epigenomics AG		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./

Examiner Signature	/Amanda Shaw/	Date Considered	03/09/2010
-----------------------	---------------	--------------------	------------

EXAMINER. Initial if reference considered, whether or not claston is in conformance with MFEP 800 Draw line through claston in facility conformance and not considered, helded copy of the form with next communication to applicant. Applicant is insigned insigned evaluate designation number (optional), 2 See March 2004 SER 100 Draw line through claston and the properties of the properties o

PTO/SB/08 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

IIIIIIDEI.	Substitute for form	1449/	•то	Complete if Known		
	INFORMATION DIS	CLO	SURE	Application Number	10/576,575	
	STATEMENT BY A	PPLI	CANT	Filing Date	April 20, 2006	
1	Date Submitted: Oct	ohar '	1 2007	First Named Inventor	Robyn Lynne Ward	
1	Date Submitted. Oct	opei	1, 2007	Art Unit	1634	
(use as many sheets	as ne	cessary)	Examiner Name	Unknown Amanda Shaw	
Sheet	2	of	2	Attorney Docket Number	037775-0107	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where publisherd.	T ⁶
	A9	ISSA et al.; "Accelerated Age-related CpG Island Methylation in Ulcerative Colitis"; "Cancer Research, Vol. 61, No. 9, May 1, 2001; pp. 3573-3577	
	A10	HIBI et al.; "A Cancer-prone Case with a Background of Methylation of p16 Tumor Suppressor Gene;" Clinical Cancer Research; Vol. 9, No. 3; March 1, 2003; pp. 1053-1056	
	A11	WONG et al.; 'Quantitative Analysis of Tumor-derived Methylated <i>P161NK4a</i> Sequences in Plasma, Serum, and Blood Cells of Hepatocellular Carcinoma Patients', 'Clinical Cancer Research; Vol. 9, No. 3, March 2003; pp. 1047-1052.	
	A12	WIDSCHWENDTER et al.; "The Potential Prognostic, Predictive, and Therapeutic Values of DNA Methylation in Cancer'," Clinical Cancer Research; An Official Journal of the American Association for Cancer Research; Vol. 8, No. 1, January 2002; pp. 17-21	
	A13	HARDEN et al.; "Molecular assessment of histologically negative lymph nodes and correlation with survival in surgically resected stage. I lung cancer using promoter methylation of multiple genes; Proceedings of the American Association for Cancer Research Annual Meeting; Vol. 43; March 2002; page 221.	
	A14	ESTELLER et al.; "Analysis of Adenomatous Polyposis Coli Promoter Hypermethylation in Human Cancer"; Cancer Research, American Association for Cancer Research; Vol. 80, No. 16; August 15, 2000; pp. 4366-4371;	
	A15	GAZZOLI et al., "A Hereditary Nonpolyposis Colorectal Carcinoma Case Associated with Hypermethylation of the MLH1 Gene in Normal Tissue and Loss of Heterozygosity of the Unmethylated Allele in the Resulting Microsatellite Instability-High Turmor'," Cancer Research, Vol. 62, No. 14; July 15, 2002; pp. 3925-3928	
	A16	CUI et al., "Loss of Imprinting in Colorectal Cancer Linked to Hypomethylation of H19 and IGF2'," Cancer Research, American Association for Cancer Research; Vol. 62; November 15, 2002; pp. 6442-6446	
	A17	SUTER et al.; "Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue;" International Journal of Colorectal Disease, Springer Verlag, Berlin, DE, Vol. 19, No. 2, March 2004; pp. 95-101	
	A18	European Search Report (EP 04 78 9594); Date of Mailing: July 3, 2007; 6 pages	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./

Examiner Signature /Amanda Shaw/	Date Considered	03/09/2010
----------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 669. Draw line through citation in rot conformance and not considered, include copy of this form with note communication to applicant. Applicant's invige citation designation number (opinional). 2 See Kindi Ooder of USPTO Patient Documents at view uppto, go or MPEP 001-04. 3 Enter Office that issued the document, by the two-letter code (WIPC) Standard \$7.3). 4 For Japanese patient applications of the patient invited produced in the patient patient invited in the patient invited invited in the patient patient